Abstract: The invention relates to a silane compound including a cycloalkyne functionality, to a method for functionalising a solid substrate, and to the solid substrate thus produced. The silane compound of the invention corresponds to the formula X-E-A-Z where X is a silyl group, E is an organic spacer group, A is a single bond or a —CONH—, —NHCO—, —OCH2CONH—, —NHCOCH2O—, —0— or —S— group, and Z is a cycloalkyne or heterocycloalkyne with at least 8 members. The invention is particularly suitable for use in the field of medicine.

Abstract: The invention relates to the use of disubstituted alkynes for the functionalisation of the surface of a substrate consisting of a semi-conductor material, with molecules of interest. According to the invention, a compound of formula A-(E1)n1-F1 is used, wherein A is a linear or cyclic disubstituted alkyne, E1 is an alkyl chain and n2 is 0 or 1, and F1 is a reactive group that can react with the reactive group F2 of a compound of formula F2-(E2)n2-X wherein E2 is an alkyl chain and X is a group having properties of interest. The invention is especially applicable to the field of molecular biology or biotechnology.

Abstract: A method for preparing nanocrystals is disclosed. According to one aspect, the noncrystals include a semiconductor ternary compound consisting of the elements A, B and C. According to another aspect, the nanocrystals include a semiconductor of formula ABC2 optionally coated with a shell, the external portion of which includes a semiconductor of formula ZnS1-xFx, with A representing a metal or metalloid in the oxidation state +I, B representing a metal or metalloid in the oxidation state +III, C representing an element in the oxidation state ?II, F representing an element in the oxidation state ?II and x being a decimal number such that 0?x<1. The disclosure also relates to the prepared nanocrystals and their uses.

Abstract: The invention relates to compounds comprising a cycloalkyne or heterocycloalkyne group and a redox group. Said compounds are of general formula (I) wherein Z is a cycloalkyne or heterocycloalkyne with at least 8 links, optionally substituted by a halogen atom or a linear or branched C1 to C5 alkyl, A is an organic structure having oxidation-reduction properties, and B is an organic link between the cycloalkyne or heterocycloalkyne cycle and the organic structure A. The invention is especially applicable to the field of molecular electronics.

Abstract: The present invention relates to fluorescent enzymatic substrates of saccharidic nature having a self-cleavable spacer arm functionalized by a fluorophore F and by at least one inhibitor of the fluorescence of F, to the use thereof for preparation of a diagnostic reagent for functional imaging in vivo, and to the diagnostic reagent for functional imaging containing at least one such enzymatic substrate.

Abstract: The invention relates to a nanocrystal formulation in the form of a nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises at least one amphiphilic lipid and at least one solubilising lipid, and in which the aqueous phase comprises a cosurfactant. The invention also relates to a method for the production of said formulation as well as uses within the fields of medical imaging, thermotherapy or phototherapy.

Abstract: The present invention relates to a therapeutic agent formulation in the form of a nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises further to the therapeutic agent, at least one amphiphilic lipid and at least one solubilising lipid, and in which the aqueous phase comprises at least one polyalkoxylated cosurfactant. The invention also relates to a preparation method and use of this formulation.

Abstract: The present invention relates to a formulation of indocyanine green in the form of a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises indocyanine green, at least one amphiphilic lipid and at least one solubilising lipid. It relates also to a process for the preparation and to the use of the formulation.

Abstract: The invention relates to a fluorescent emulsion, to its uses and to labelling reagents comprising it.

Abstract: The present invention is targeted at a novel coupling method of 1,3-dipolar cycloaddition type which is of particular use for the functionalization of biological molecules, such as, for example, proteins, enzymes or nucleic acids, insofar as it can be carried out in an aqueous medium and at ambient temperature.

Abstract: The invention relates to a fluorescent emulsion, to a diagnostic reagent containing the same, and to the use thereof in the preparation of a diagnostic reagent for in vivo fluorescence imaging.

Abstract: The present invention relates to a method of optically imaging at least one biological tissue, in particular to define areas of interest of tissue(s) to be analyzed by tomography.

Abstract: The present invention aims to provide a method of use for surface-modifying a semiconductor nanocrystal comprising at least the steps consisting in having a semiconductor nanocrystal, the organic coating layer of which is provided, at the outer surface of the nanocrystal, with at least one reactive group G1 that reacts according to a cycloaddition reaction of click chemistry type; and bringing said nanocrystal together with an adjoining material provided at the surface with at least one G2 group complementary to the G1 group with respect to said click chemistry reaction, under conditions favourable to the interaction of said G1 and G2 groups, characterized in that said G1 and G2 groups are respectively an azide and a strained cycloalkynyl radical, or vice versa.

Abstract: The present invention relates to a method for preparing nano-emulsions comprising at least one aqueous continuous phase and at least one oily dispersed phase, comprising the steps of: (i) preparing the oily phase comprising at least one amphiphilic lipid and at least one solubilising lipid; (ii) dispersing the oily phase in an aqueous phase under the effect of sufficient shear force to form a nano-emulsion; and (iii) recovering the nano-emulsion thus formed.

Abstract: The present invention relates to fluorescent enzymatic substrates of saccharidic nature having a self-cleavable spacer arm functionalized by a fluorophore F and by at least one inhibitor of the fluorescence of F, to the use thereof for preparation of a diagnostic reagent for functional imaging in vivo, and to the diagnostic reagent for functional imaging containing at least one such enzymatic substrate.

Abstract: The invention concerns saccharide type fluorescent enzymatic substrates comprising on the same saccharide unit a fluorophor F1 and an inhibitor of the fluorescence of F1, and their use for preparing a diagnostic reagent for in vivo functional imaging, as well as a diagnostic reagent containing at least such an enzymatic substrate.

Abstract: The invention concerns the field of molecular probe architecture for in vivo imaging. More particularly, the invention concerns molecular constructs providing an imaging function activable in intracellular environment, said constructs being further bound to a vector which enables certain cells to be targeted, and said cells to be internalized. The inventive fluorescence probes enable in particular images of certain targeted tissues to be formed, while maintaining a low background noise level and, preferably, while obtaining at the targeted tissue, an imaging signal increasing in time.

Abstract: The present invention relates to a method of optically imaging at least one biological tissue, in particular to define areas of interest of tissue(s) to be analyzed by tomography.

Abstract: The invention relates to a method of preparing DNA fragments by selective fragmentation of nucleic acid fragments. The inventive method comprises a first selection step involving selection of short fragments, consisting in: a) preparing first double-stranded DNA fragments F1 using at least one restriction enzyme E1 which can randomly fragment the nucleic acid sample to be analysed, by generating said DNA fragments F1 with blunt or cohesive ends; b) ligating the ends of the DNA fragments F1 obtained in step (a) to at least one adapter AA?; c) cleaving the DNA fragments F1 obtained in step (b) using a restriction enzyme E2, such as to select a fraction of short fragments F2; and d) using any suitable means to purify the aforementioned fraction of short fragments F2.